Inhibitor and substrate cooperate to inhibit amyloid fibril elongation of α-synuclein.

Chemical Science
Emil Dandanell AgerschouWolfgang Hoyer

Abstract

In amyloid fibril elongation, soluble growth substrate binds to the fibril-end and converts into the fibril conformation. This process is targeted by inhibitors that block fibril-ends. Here, we investigated how the elongation of α-synuclein (αS) fibrils, which are associated with Parkinson's disease and other synucleinopathies, is inhibited by αS variants with a preformed hairpin in the critical N-terminal region comprising residues 36-57. The inhibitory efficiency is strongly dependent on the specific position of the hairpin. We find that the inhibitor and substrate concentration dependencies can be analyzed with models of competitive enzyme inhibition. Remarkably, the growth substrate, i.e., wild-type αS, supports inhibition by stabilizing the elongation-incompetent blocked state. This observation allowed us to create inhibitor-substrate fusions that achieved inhibition at low nanomolar concentration. We conclude that inhibitor-substrate cooperativity can be exploited for the design of fibril growth inhibitors.

References

Nov 1, 1968·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·E D Eanes, G G Glenner
Aug 28, 1997·Nature·M G SpillantiniM Goedert
Mar 6, 1998·Protein Engineering·K GunasekaranP Balaram
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Nov 25, 1998·Protein Science : a Publication of the Protein Society·E G HutchinsonD N Woolfson
May 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·A G CochranM A Starovasnik
Feb 3, 2004·Annals of Neurology·Juan J ZarranzJusto G de Yebenes
Jun 9, 2004·Journal of Molecular Biology·Wolfgang HoyerThomas M Jovin
Nov 10, 2004·Journal of Molecular Biology·Tadato BanYuji Goto
Feb 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Li-Mei YanAphrodite Kapurniotu
Oct 19, 2007·Chemistry : a European Journal·Clara M SantiveriM Angeles Jiménez
Dec 29, 2007·Proceedings of the National Academy of Sciences of the United States of America·Miklós S Z KellermayerBotond Penke
Sep 28, 2010·Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics·Jesper Ferkinghoff-BorgMogens H Jensen
Sep 30, 2010·Physical Review Letters·Alexander K BuellTuomas P J Knowles
Jun 10, 2011·Journal of the American Chemical Society·Andrew J BaldwinChristopher M Dobson
Mar 5, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Silke Appel-CresswellMatthew J Farrer
Mar 26, 2013·Annals of Neurology·Suzanne LesageUNKNOWN French Parkinson's Disease Genetics Study Group
Jul 23, 2013·PloS One·Katazyna MiltoVytautas Smirnovas
Feb 25, 2014·Trends in Pharmacological Sciences·Paolo ArosioTuomas P J Knowles
Mar 14, 2014·Angewandte Chemie·Ewa A MireckaWolfgang Hoyer
May 13, 2014·Proceedings of the National Academy of Sciences of the United States of America·Alexander K BuellChristopher M Dobson
May 24, 2014·Nature Reviews. Molecular Cell Biology·Tuomas P J KnowlesChristopher M Dobson
Feb 11, 2015·Journal of Molecular Biology·Michael M WördehoffEva Birkmann
Jun 30, 2015·Angewandte Chemie·Hamed ShaykhalishahiWolfgang Hoyer
Jul 29, 2015·Proceedings of the National Academy of Sciences of the United States of America·Pietro SormanniMichele Vendruscolo
Jan 8, 2016·Nature Protocols·Georg MeislTuomas P J Knowles
Jan 26, 2016·Nature·Francois-Xavier TheilletPhilipp Selenko
Jun 20, 2017·Nature Chemical Biology·Mike SleutelHan Remaut
Sep 18, 2017·Journal of Molecular Biology·Michael M WördehoffWolfgang Hoyer
Jul 4, 2018·ELife·Ricardo Guerrero-FerreiraHenning Stahlberg
Jul 7, 2018·Chemical Communications : Chem Comm·Mattias TörnquistSara Linse
Aug 7, 2018·Chemical Science·Filip HaseckeMartin Muschol
Sep 22, 2018·Nature Reviews. Molecular Cell Biology·Matthew G IadanzaSheena E Radford
Jun 30, 2019·Journal of Neurochemistry·Parvez AlamDaniel E Otzen
Oct 19, 2019·Journal of Medicinal Chemistry·Yevhenii A KyriukhaVolodymyr V Shvadchak
Oct 28, 2019·The Biochemical Journal·Alexander K Buell
Dec 7, 2019·Journal of Molecular Biology·Kseniia AfitskaVolodymyr V Shvadchak

❮ Previous
Next ❯

Citations

May 11, 2021·Journal of Medicinal Chemistry·Anastasiia PrissVolodymyr V Shvadchak
Oct 24, 2021·Journal of Neurochemistry·Maksym GalkinVolodymyr V Shvadchak

❮ Previous
Next ❯

Methods Mentioned

BETA
NMR
AFM
atomic force microscopy

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.